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Developing the host for Targeted Integration cell line development 
 
Michelle Zhou, Isla Cheung, Shirley Yip, Mike Laird, John Joly, Brad Snedecor, 
Amy Shen, and Yongping Crawford 
 
Unlike the conventional random integration (RI) cell line development (CLD), the 
targeted integration (TI) CLD introduces the transgene at a predetermined “hot-
spot” in the CHO genome with a defined copy number (1-2 copies).  Given the 
low copy number and the pretested integration site, TI cell lines likely exhibit 
better stability compared to RI cell lines.   In this study, we performed a genome 
wide screening using transposon based cassette integration and established a TI 
host (255-3) that has a single landing cassette inserted in its genome.  Host 255-
3 was able to support the CLD for three test molecules with product titers similar 
to those of the corresponding RI cell lines.  For two regular antibody test cases, 
the top four TI cell lines achieved ~4-5g/L.  For a proven difficult to express 
antibody, the top four TI lines achieved ~1-1.2g/L.   The product titer for this hard 
to express molecule was increased 3-fold with additional vector 
improvement.  Moreover, the timeline for CLD was shortened by ~2 weeks and 
resources required per cell line were substantially reduced using the TI 
method.  Together these data indicate that the TI host we developed can be a 
suitable host to support our clinical / commercial CLD. 
